Filing Flows › Bionano Genomics (BNGO) › Q2 2025
Bionano Genomics (BNGO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Bionano Genomics (BNGO) reported revenue of $6.7M for the second quarter 2025 (Q2 2025), -13% from a year earlier and +4% from the quarter before. Operating margin was -115.8%, net loss $6.9M (101.8% of revenue).
Bionano Genomics, Q2 2025: revenue $6.7M (-13% year over year), operating margin -115.8%, net loss $6.9M, operating cash flow −$3.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.7M | +4% | -13% |
| Operating profit | −$7.8M | — | — |
| Net earnings | −$6.9M | — | — |
| Operating cash flow | −$3.5M | — | — |
What changed
Revenue was $6.7M in Q2 2025, down 13% year over year and up 4% from the previous quarter. Consumables was the largest line at 49% of revenue. Instruments lost $861K year over year (down 38%), 83% of the total change.
Operating costs exceeded revenue by $7.8M, an operating margin of -115.8%. Total costs fell 41% while revenue fell 13%. The quarter ended with a net loss of $6.9M, wider than the previous quarter's $3.1M loss.
Operating cash flow was −$3.5M. Non-cash charges added back $2.4M of depreciation and amortization and $1.1M of share-based compensation.
Questions
What was Bionano Genomics' revenue in the second quarter 2025?
Bionano Genomics (BNGO) reported revenue of $6.7M for the second quarter 2025 (Q2 2025), -13% from a year earlier and +4% from the quarter before.
Was Bionano Genomics profitable in the second quarter 2025?
Operating loss was $7.8M (-115.8% of revenue) and net loss $6.9M.
Source: Bionano Genomics 10-Q on SEC EDGAR.